{"entity":{"type":"insider","cik":"0001279309","url":"/insider/0001279309","json_url":"/insider/0001279309.json","name":"KING THOMAS BRAXTON","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":48,"n_filings":13,"first":"2007-08-13","last":"2025-09-08","span_basis":"filed_date"},"name_variants":[{"name":"KING THOMAS BRAXTON","source":"filing","n_filings":13,"first_seen":"2007-08-13","last_seen":"2025-09-08"}],"transactions":[{"id":4620408,"accession":"0000950170-25-113591","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-113591","line_url":"/filing/0000950170-25-113591#line-2","is_derivative":false,"issuer_cik":"0000949858","issuer_name":"ACHIEVE LIFE SCIENCES, INC.","issuer_ticker":"ACHV","issuer_name_source":null,"issuer_url":"/issuer/0000949858","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":139858.0,"shares_display":"139,858","price_per_share":2.77,"price_display":"2.77","price_state":"stated","total_value":387406.66,"total_display":"387,406.66","total_whole":"387,407","shares_owned_after":315142.0,"shares_owned_after_display":"315,142","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-04","filed_date":"2025-09-08","scope":"insider"},{"id":9268674,"accession":"0001209191-13-038370","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-13-038370","line_url":"/filing/0001209191-13-038370#line-3","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2420.0,"shares_display":"2,420","price_per_share":4.49,"price_display":"4.49","price_state":"stated","total_value":10865.8,"total_display":"10,865.80","total_whole":"10,866","shares_owned_after":215000.0,"shares_owned_after_display":"215,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-26","filed_date":"2013-07-30","scope":"insider"},{"id":4458657,"accession":"0001209191-13-038079","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-13-038079","line_url":"/filing/0001209191-13-038079#line-3","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2420.0,"shares_display":"2,420","price_per_share":4.49,"price_display":"4.49","price_state":"stated","total_value":10865.8,"total_display":"10,865.80","total_whole":"10,866","shares_owned_after":215000.0,"shares_owned_after_display":"215,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-26","filed_date":"2013-07-26","scope":"insider"},{"id":9268676,"accession":"0001209191-13-038370","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-13-038370","line_url":"/filing/0001209191-13-038370#line-2","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12580.0,"shares_display":"12,580","price_per_share":4.498,"price_display":"4.50","price_state":"stated","total_value":56584.84,"total_display":"56,584.84","total_whole":"56,585","shares_owned_after":212580.0,"shares_owned_after_display":"212,580","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-25","filed_date":"2013-07-30","scope":"insider"},{"id":4458652,"accession":"0001209191-13-038079","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-13-038079","line_url":"/filing/0001209191-13-038079#line-2","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12580.0,"shares_display":"12,580","price_per_share":4.498,"price_display":"4.50","price_state":"stated","total_value":56584.84,"total_display":"56,584.84","total_whole":"56,585","shares_owned_after":212580.0,"shares_owned_after_display":"212,580","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-25","filed_date":"2013-07-26","scope":"insider"},{"id":9268675,"accession":"0001209191-13-038370","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-13-038370","line_url":"/filing/0001209191-13-038370#line-1","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":4.476,"price_display":"4.48","price_state":"stated","total_value":111900.0,"total_display":"111,900.00","total_whole":"111,900","shares_owned_after":200000.0,"shares_owned_after_display":"200,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-24","filed_date":"2013-07-30","scope":"insider"},{"id":4458643,"accession":"0001209191-13-038079","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-13-038079","line_url":"/filing/0001209191-13-038079#line-1","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":4.476,"price_display":"4.48","price_state":"stated","total_value":111900.0,"total_display":"111,900.00","total_whole":"111,900","shares_owned_after":200000.0,"shares_owned_after_display":"200,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-24","filed_date":"2013-07-26","scope":"insider"},{"id":3382882,"accession":"0001209191-12-043660","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-12-043660","line_url":"/filing/0001209191-12-043660#line-3","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":4.1364,"price_display":"4.14","price_state":"stated","total_value":41364.0,"total_display":"41,364.00","total_whole":"41,364","shares_owned_after":10229.0,"shares_owned_after_display":"10,229","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-08-27","filed_date":"2012-08-29","scope":"insider"},{"id":2820330,"accession":"0001209191-12-033064","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-12-033064","line_url":"/filing/0001209191-12-033064#line-1","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":65516.0,"shares_display":"65,516","price_per_share":0.3381,"price_display":"0.34","price_state":"stated","total_value":22150.9596,"total_display":"22,150.96","total_whole":"22,151","shares_owned_after":202325.0,"shares_owned_after_display":"202,325","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-06-06","filed_date":"2012-06-08","scope":"insider"},{"id":9266911,"accession":"0001209191-09-058156","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-09-058156","line_url":"/filing/0001209191-09-058156#line-3","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22861.0,"shares_display":"22,861","price_per_share":2.1269,"price_display":"2.13","price_state":"stated","total_value":48623.0609,"total_display":"48,623.06","total_whole":"48,623","shares_owned_after":75845.0,"shares_owned_after_display":"75,845","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-18","filed_date":"2009-12-21","scope":"insider"},{"id":5675260,"accession":"0001209191-09-058001","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-09-058001","line_url":"/filing/0001209191-09-058001#line-3","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22858.0,"shares_display":"22,858","price_per_share":2.1269,"price_display":"2.13","price_state":"stated","total_value":48616.6802,"total_display":"48,616.68","total_whole":"48,617","shares_owned_after":75851.0,"shares_owned_after_display":"75,851","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-18","filed_date":"2009-12-18","scope":"insider"},{"id":9266912,"accession":"0001209191-09-058156","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-058156","line_url":"/filing/0001209191-09-058156#line-2","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7893.0,"shares_display":"7,893","price_per_share":2.2007,"price_display":"2.20","price_state":"stated","total_value":17370.1251,"total_display":"17,370.13","total_whole":"17,370","shares_owned_after":98706.0,"shares_owned_after_display":"98,706","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-17","filed_date":"2009-12-21","scope":"insider"},{"id":5675259,"accession":"0001209191-09-058001","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-058001","line_url":"/filing/0001209191-09-058001#line-2","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7892.0,"shares_display":"7,892","price_per_share":2.2007,"price_display":"2.20","price_state":"stated","total_value":17367.9244,"total_display":"17,367.92","total_whole":"17,368","shares_owned_after":98709.0,"shares_owned_after_display":"98,709","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-17","filed_date":"2009-12-18","scope":"insider"},{"id":9266910,"accession":"0001209191-09-058156","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-058156","line_url":"/filing/0001209191-09-058156#line-1","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14246.0,"shares_display":"14,246","price_per_share":2.4071,"price_display":"2.41","price_state":"stated","total_value":34291.5466,"total_display":"34,291.55","total_whole":"34,292","shares_owned_after":106599.0,"shares_owned_after_display":"106,599","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-16","filed_date":"2009-12-21","scope":"insider"},{"id":5675258,"accession":"0001209191-09-058001","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-058001","line_url":"/filing/0001209191-09-058001#line-1","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14244.0,"shares_display":"14,244","price_per_share":2.4071,"price_display":"2.41","price_state":"stated","total_value":34286.7324,"total_display":"34,286.73","total_whole":"34,287","shares_owned_after":106601.0,"shares_owned_after_display":"106,601","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-16","filed_date":"2009-12-18","scope":"insider"},{"id":5967920,"accession":"0001209191-09-047813","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-047813","line_url":"/filing/0001209191-09-047813#line-1","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":64655.0,"shares_display":"64,655","price_per_share":2.32,"price_display":"2.32","price_state":"stated","total_value":149999.6,"total_display":"149,999.60","total_whole":"150,000","shares_owned_after":120845.0,"shares_owned_after_display":"120,845","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-10-05","filed_date":"2009-10-06","scope":"insider"},{"id":3204259,"accession":"0001209191-08-046593","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-08-046593","line_url":"/filing/0001209191-08-046593#line-1","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":5.6722,"price_display":"5.67","price_state":"stated","total_value":70902.5,"total_display":"70,902.50","total_whole":"70,903","shares_owned_after":116107.0,"shares_owned_after_display":"116,107","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-08-11","filed_date":"2008-08-11","scope":"insider"},{"id":3183576,"accession":"0001209191-08-029578","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001209191-08-029578","line_url":"/filing/0001209191-08-029578","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":6.11808,"price_display":"6.12","price_state":"stated","total_value":76476.0,"total_display":"76,476.00","total_whole":"76,476","shares_owned_after":136907.0,"shares_owned_after_display":"136,907","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-05-12","filed_date":"2008-05-13","scope":"insider","n_lines":10},{"id":2619334,"accession":"0001209191-08-009472","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001209191-08-009472","line_url":"/filing/0001209191-08-009472","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":6.6644864,"price_display":"6.66","price_state":"stated","total_value":83306.08,"total_display":"83,306.08","total_whole":"83,306","shares_owned_after":150871.0,"shares_owned_after_display":"150,871","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-02-11","filed_date":"2008-02-12","scope":"insider","n_lines":13},{"id":7301721,"accession":"0001209191-07-063215","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-07-063215","line_url":"/filing/0001209191-07-063215#line-1","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":7.2,"price_display":"7.20","price_state":"stated","total_value":90000.0,"total_display":"90,000.00","total_whole":"90,000","shares_owned_after":156107.0,"shares_owned_after_display":"156,107","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-11-09","filed_date":"2007-11-13","scope":"insider"},{"id":7024111,"accession":"0001209191-07-047747","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-07-047747","line_url":"/filing/0001209191-07-047747","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":9.1288,"price_display":"9.13","price_state":"stated","total_value":91288.0,"total_display":"91,288.00","total_whole":"91,288","shares_owned_after":176542.0,"shares_owned_after_display":"176,542","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-08-09","filed_date":"2007-08-13","scope":"insider","n_lines":6},{"id":7024097,"accession":"0001209191-07-047747","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-07-047747","line_url":"/filing/0001209191-07-047747#line-1","is_derivative":false,"issuer_cik":"0001279309","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001279309","owner_cik":"0001279309","owner_name":"KING THOMAS BRAXTON","owner_display_name":"KING THOMAS BRAXTON","owner_url":"/insider/0001279309","role":"Director, Officer (Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":9.25,"price_display":"9.25","price_state":"stated","total_value":23125.0,"total_display":"23,125.00","total_whole":"23,125","shares_owned_after":171442.0,"shares_owned_after_display":"171,442","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-08-08","filed_date":"2007-08-13","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":48,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":7,"open_market":true},{"code":"S","label":"Open-market sale","n":41,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":48},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000949858","name":"ACHIEVE LIFE SCIENCES, INC.","url":"/issuer/0000949858","role":"Director","n_filings":1,"first_seen":"2025-09-08","last_seen":"2025-09-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001344413","name":"Alexza Pharmaceuticals Inc.","url":"/issuer/0001344413","role":"Director, Officer (Pres & CEO)","n_filings":12,"first_seen":"2007-08-13","last_seen":"2013-07-30"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001279309","retrieved_at":"2026-08-22T18:54:07+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}